Nephrology Drugs Market Size to Grow US$ 27.2 Billion By 2032

The global nephrology drugs market size was approximate at US$ 15.9  billion in 2022 and is anticipated to grow US$ 27.2 billion by 2032, registering a compound annual growth rate of 5.52% from 2023 to 2032.

The nephrology drugs market report covering various industry elements and growth trends helpful for predicting the market’s future.

The study provides a strong base for the nephrology drugs market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2032.

This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2023 g0066ztr to 2032. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the nephrology drugs report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the nephrology drugs market have been studied and analysed across many developments.

Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2577

Nephrology Drugs Market Report Scope

Also read: Palm Oil Market Size to Grow US$ 106.3 Billion By 2032

Research Approach

The comprehensive report on the global nephrology drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global nephrology drugs market.

It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Key Players

• AstraZeneca
• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Amgen Inc.
• F. Hoffmann-La Roche
• FibroGen Inc.
• Johnson & Johnson Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Limited
• Reata Pharmaceuticals, Inc.
• GlaxoSmithKline plc.
• Ardelyx, Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Novartis AG

Nephrology Drugs Market Segmentations

By Drug Class

• ACE Inhibitors
• Angiotensin Receptor Blockers (ARBs)
• B-Blockers
• Calcium Channel Blockers
• Loop Diuretics
• Erythropoiesis-Stimulating Agents (ESAs)
• Phosphate Binders
• Others

By Route of Administration

• Oral
• Subcutaneous
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Nephrology Drugs Market 

5.1. COVID-19 Landscape: Nephrology Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Nephrology Drugs Market, By Drug Class

8.1. Nephrology Drugs Market, by Drug Class, 2023-2032

8.1.1 ACE Inhibitors

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Angiotensin Receptor Blockers (ARBs)

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. B-Blockers

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Calcium Channel Blockers

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Loop Diuretics

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Erythropoiesis-Stimulating Agents (ESAs)

8.1.6.1. Market Revenue and Forecast (2020-2032)

8.1.7. Phosphate Binders

8.1.7.1. Market Revenue and Forecast (2020-2032)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Nephrology Drugs Market, By Route of Administration

9.1. Nephrology Drugs Market, by Route of Administration, 2023-2032

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Subcutaneous

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Intravenous

9.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Nephrology Drugs Market, By Distribution Channel 

10.1. Nephrology Drugs Market, by Distribution Channel, 2023-2032

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Nephrology Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 12. Company Profiles

12.1. AstraZeneca

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. AbbVie Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Akebia Therapeutics, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Amgen Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. F. Hoffmann-La Roche

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. FibroGen Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Johnson & Johnson Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Pfizer Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Teva Pharmaceutical Industries Limited

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Reata Pharmaceuticals, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global nephrology drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for nephrology drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com